Effect of royal jelly capsule on quality of life of patients with multiple sclerosis: A double-blind randomized controlled clinical trial

IRCMJ logo
PDF
HTML

Keywords

Multiple Sclerosis
Royal Jelly
Quality of Life

How to Cite

Oshvandi, K., Aghamohammadi, M., Kazemi, F., Masoumi, S. Z., Mazdeh, M., & Molavi Vardanjani, M. (2020). Effect of royal jelly capsule on quality of life of patients with multiple sclerosis: A double-blind randomized controlled clinical trial. Iranian Red Crescent Medical Journal, 22(10). https://doi.org/10.32592/ircmj.2020.22.10.74

Abstract

Background: Among the most important chronic diseases is multiple sclerosis (MS) leading to physical disability and decrease in the patientsʼ quality of life.

Objectives: The present study aimed to investigate the effect of the royal jelly capsule on the life quality of patients with MS.

Methods: This randomized clinical trial study was conducted on a total of 100 patients referring to the MS Society of Hamadan, Iran, in 2018. Allocation sequences were determined using block randomization with a block size of 4, and the subjects were assigned to the intervention and control groups according to a predetermined sequence. The intervention group received one royal jelly capsule (500 mg) daily, and the control group received a placebo capsule for 90 days. The life quality of the patients and their daily activities were evaluated using the specific questionnaire for the life quality of the patients with MS and Barthel Index of Daily Living Activities before and after the intervention. Data analysis was performed by Stata software (version 13) and appropriate statistical tests with a significance level of 0.05.

Results: The comparison of the mean score of the patientsʼ life quality showed that it was higher in the experimental group in the post-intervention (66.51±15.08) than that reported for the control group (51.31±15.08) after controlling possible confounding factors, which was statistically significant (P<0.001). Furthermore, Cohen's d (1.01; 95% CI: 0.59-1.42) also indicated the intended large effect size of the intervention. The comparison of daily activity status scores between the two groups also demonstrated an improvement in the experimental group (18.76±1.44), compared to that of the control group (16.96±3.01), which was statistically significant (P=0.001).

Conclusions: Based on the findings of the current study, it can be concluded that the use of the royal jelly supplement can be effective in the improvement of the life quality of the patients with MS.

https://doi.org/10.32592/ircmj.2020.22.10.74
PDF
HTML

References

  1. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851-62. doi: 10.1056/NEJMoa073493. [PubMed: 17660530].
  2. Poorolajal J, Mazdeh M, Saatchi M, Ghane ET, Biderafsh A, Lotfi B, et al. Multiple sclerosis associated risk factors: a case-control study. Iran J Public Health. 2015;44(11):1498-505. [PubMed: 26744707].
  3. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol. 2013;70(5-6):356-63. doi: 10.1159/000355140. [PubMed: 24192707].
  4. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training onfitness and quality of life in multiple sclerosis. Ann Neurol. 1996;39(4):432-41. doi: 10.1002/ana.410390405. [PubMed: 8619521].
  5. Janssens AC, Doorn PV, Boer JB, van der Meché FG, Passchier J, Hintzen RQ. Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners. Acta Neurol Scand. 2003;108(6):389-95. doi: 10.1034/j.1600-0404.2003.00166.x. [PubMed: 14616290].
  6. Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, et al. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology. 2001;57(10):1870-5. doi: 10.1212/wnl.57.10.1870. [PubMed: 11723278].
  7. Al-Waili N, Salom K, Al-Ghamdi AA. Honey for wound healing, ulcers, and burns; data supporting its use in clinical practice. Sci World J. 2011;11:766-87. doi: 10.1100/tsw.2011.78. [PubMed: 21479349].
  8. Payamani F, Nazari A, Noktehdan H, Ghadiriyan F, Karami K. Complementary therapy in patients with multiple sclerosis. Iran J Nurs. 2012;25(77):12-20.
  9. Nagai T, Sakai M, Inoue R, Inoue H, Suzuki N. Antioxidative activities of some commercially honeys, royal jelly, and propolis. Food Chem. 2001;75(2):237-40. doi: 10.1016/S0308-8146(01)00193-5.
  10. Barkhordari F, Taavoni S, Haghani H, Gooshe Gir A. Effect of oral Royal jelly on edema of premenstrual syndrome. Complementary Med J. 2013;3(1):355-65.
  11. Morita H, Ikeda T, Kajita K, Fujioka K, Mori I, Okada H, et al. Effect of royal jelly ingestion for six months on healthy volunteers. Nutr J. 2012;11(1):77. doi: 10.1186/1475-2891-11-77. [PubMed: 22995464].
  12. Meng G, Wang H, Pei Y, Li Y, Wu H, Song Y, et al. Effects of protease-treated royal jelly on muscle strength in elderly nursing home residents: a randomized, double-blind, placebo-controlled, dose-response study. Sci Rep. 2017;7(1):11416. doi: 10.1038/s41598-017-11415-6. [PubMed: 28900247].
  13. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The multiple sclerosis impact scale (MSIS-29) a new patient-based outcome measure. Brain. 2001;124(5):962-73. doi: 10.1093/brain/124.5.962. [PubMed: 11335698].
  14. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL index: a reliability study. Int Disabil Stud. 1988;10(2):61-3. doi: 10.3109/09638288809164103. [PubMed: 3403500].
  15. Ysrraelit MC, Fiol MP, Gaitán MI, Correale J. Quality of life assessment in multiple sclerosis: different perception between patients and neurologists. Front Neurol. 2018;8:729. doi: 10.3389/fneur.2017.00729. [PubMed: 29375468].
  16. Seyyedi F, Kopaei MR, Miraj S. Comparison between vaginal royal jelly and vaginal estrogen effects on quality of life and vaginal atrophy in postmenopausal women: a clinical trial study. Electron Physician. 2016;8(11):3184-92. doi: 10.19082/3184. [PubMed: 28070251].
  17. Mobedi Z, Soleimani F, Rafieian-Kopaei M, Parvin N, Taheri E. The effect of oral royal jelly on clinical disease activity index (CDAI) and morning stiffness in patients with rheumatoid arthritis (RA); A randomized double-blind, placebo-controlled trial. J Isfahan Med Sch. 2013;31(252):1428-34.
  18. Meng G, Wang H, Pei Y, Li Y, Wu H, Song Y, et al. Effects of protease-treated royal jelly on muscle strength in elderly nursing home residents: a randomized, double-blind, placebo-controlled, dose-response study. Sci Rep. 2017;7(1):11416. doi: 10.1038/s41598-017-11415-6. [PubMed: 28900247].
  19. Erem C, Deger O, Ovali E, Barlak Y. The effects of royal jelly on autoimmunity in Graves' disease. Endocrine. 2006;30(2):175-83. doi: 10.1385/ENDO:30:2:175. [PubMed: 17322576].
  20. Constantin MM, Nita IE, Olteanu R, Constantin T, Bucur S, Matei C, et al. Significance and impact of dietary factors on systemic lupus erythematosus pathogenesis. Exp Ther Med. 2019;17(2):1085-90. doi: 10.3892/etm.2018.6986. [PubMed: 30679978].